Expression of ERCC1, p53, and Class III β-tubulin do not reveal chemoresistance in endometrial cancer results from an immunohistochemical study

International Journal of Gynecological Cancer

Volumn 21, Issue 6, 2011, Pages 1071-1077

  Vandenput, Ingrid ^a   Capoen, An ^b   Coenegrachts, Lieve ^a   Verbist, Godelieve ^a   Moerman, Philippe ^b   Vergote, Ignace ^a   Amant, Frédéric ^a,c  

^a Katholieke Universiteit   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Class III tubulin; Endometrial cancer; ERCC1; P53; Paclitaxel; Platinum based

Indexed keywords

ANTINEOPLASTIC AGENT; BETA TUBULIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PACLITAXEL; PROTEIN P53; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; EARLY CANCER; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; RETROSPECTIVE STUDIES; TUBULIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 83055169906     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318218f28b     Document Type: Article

References (25)

1. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005;366:591Y605.
2. Aapro M, van Wijk F, Bolis G, et al; EORTC Group. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definite results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol. 2003;14:441Y448. (Pubitemid 36367423)
3. Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004;22:3902Y3908. (Pubitemid 41079871)
4. Hoskins P, Swenerton K, Pike J, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol. 2001;19:4048Y4053. (Pubitemid 32976691)
5. Powell MA, Filiaci VL, Rose PG, et al. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol. 2010;28:2727Y2731.
6. Tropé C, Alektiar K, Sabbatini P, et al. Corpus: epithelial tumors. In: Hoskins W, Perez C, eds. Principles and Practice of Gynecologic Oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005:856.
7. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 1998;24:331Y344. (Pubitemid 28537769)
8. Sancar A. Mechanisms of DNA excision repair. Science. 1994;266:1954Y1956.
9. Olaussen K, Dunant A, Fouret P, et al; IALT Bio Investigators. DNA repair by ERCC1 in nonYsmall-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983Y991.
10. Azuma K, Komohara Y, Sasada T, et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in nonYsmall cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci. 2007;98:1336Y1343. (Pubitemid 47241754)
11. Ikeda S, Takabe K, Suzuki K. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable nonYsmall cell lung cancer. Pathol Int. 2009;59:863Y867.
12. Azuma K, Sasada T, Kawahara A, et al. Expression of ERCC1 and class III beta-tubulin in nonYsmall cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer. 2009;64:326Y333.
13. Azuma K, Sasada T, Kawahara A, et al. Expression of ERCC1 and class III beta-tubulin in nonYsmall cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer Chemother Pharmacol. 2009;64:565Y573.
14. Okuda K, Sasaki H, Dumontet C, et al. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected nonYsmall cell lung cancer. Lung Cancer. 2008;62:105Y112.
15. Manic S, Gatti L, Carenini N, et al. Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repairs. Current Cancer Drug Targets. 2003;3:21Y29. (Pubitemid 36119418)
16. Sève P, Dumontet C. Is class III A-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 2008;9:168Y175. (Pubitemid 351150128)
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205Y216. (Pubitemid 30099779)
18. Leake R, Barnes D, Pinder S, et al. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. J Clin Pathol. 2000;53:634Y635. (Pubitemid 30640178)
19. Steffensen KD, WaldstrLm M, Jakobsen A. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer. 2009;19: 820Y825.
20. Zhu C, Luo J, Shi H, et al. Expression of tubulin, p53, ki67, receptors for estrogen, and progesterone in endometrial cancer. Eur J Gynaecol Oncol. 2009;30:514Y517.
21. Engelsen I, Akslen L, Salvesen H. Biologic markers in endometrial cancer treatment. APMIS. 2009;117:693Y707.
22. Brabec V, Kasparkova J. Molecular aspects of resistance to antitumor platinum drugs. Drug Resist Updat. 2002;5:147Y161. (Pubitemid 35033806)
23. Resnick KE, Frankel WL, Morrison CD, et al. Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer. Gynecol Oncol. 2010;117:234Y238.
24. Chaudhry P, Asselin E. Resistance to chemotherapy and hormone therapy in endometrial cancer. Endocr Relat Cancer. 2009;16:363Y380.
25. Jiang T, Chen N, Zhao F, et al. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 2010;70:5486.